Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma

被引：7

作者：

Qin, Shu-Kui ^{[1
]}

Jin, Jie ^{[2
]}

Guo, Jun ^{[3
]}

Wang, Jin-Wan ^{[4
,5
]}

Zhou, Fang-Dian ^{[6
]}

Huang, Yi-Ran ^{[7
]}

Ren, Xiu-Bao ^{[8
]}

Ye, Ding-Wei ^{[9
]}

Pan, Sharon ^{[10
]}

Sajben, Peter ^{[10
]}

Wang, Qiao ^{[11
]}

机构：

[1] Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[2] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China

[3] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China

[4] Chinese Acad Med Sci, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China

[5] Peking Union Med Coll, Beijing, Peoples R China

[6] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[7] Shanghai Renji Hosp, Dept Urol, Shanghai, Peoples R China

[8] Tianjin Med Univ, Canc Inst & Hosp, Dept Biol Treatment, Tianjin, Peoples R China

[9] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China

[10] Pfizer Inc, New York, NY 10017 USA

[11] Pfizer Global Res & Dev, Shanghai, Peoples R China

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 18期

关键词：

Chinese; metastasis; renal cell carcinoma; sunitinib; targeted therapy; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS; SURVIVAL; HYPERTENSION; BIOMARKERS; SORAFENIB; AXITINIB; THERAPY;

D O I：

10.2217/fon-2017-0733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We report the first prospective study of sunitinib for metastatic renal cell carcinoma (mRCC) in China. Methods: Chinese mRCC patients received first-line sunitinib 50 mg daily (4/2 regimen). Overall survival (OS), progression-free survival (PFS), objective response rate and safety were assessed. Potential efficacy biomarkers were explored in post hoc analyses. Results: Median PFS was 61.7 weeks; median OS was 133.4 weeks; objective response rate was 31.1%. Most frequent adverse events (AEs) were: hand-foot syndrome (63.8%), decreased white blood cell count (52.4%), fatigue (51.4%) and decreased platelet count (51.4%). AEs were identified that predicted longer PFS and OS. Conclusion: Sunitinib showed efficacy and manageable AE profile in treatment-naive Chinese mRCC patients. Larger prospective studies are required to confirm identified AEs as predictors of efficacy.

引用

页码：1835 / 1845

页数：11

共 32 条

[21] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[22] Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Olsen, Mark R. ;

Hudes, Gary R. ;

Burke, John M. ;

Edenfield, William J. ;

Wilding, George ;

Agarwal, Neeraj ;

Thompson, John A. ;

Cella, David ;

Bello, Akintunde ;

Korytowsky, Beata ;

Yuan, Jinyu ;

Valota, Olga ;

Martell, Bridget ;

Hariharan, Subramanian ;

Figlin, Robert A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) :1371-1377

[23] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Pili, Roberto ;

Bjarnason, Georg A. ;

Garcia-del-Muro, Xavier ;

Sosman, Jeffrey A. ;

Solska, Ewa ;

Wilding, George ;

Thompson, John A. ;

Kim, Sindy T. ;

Chen, Isan ;

Huang, Xin ;

Figlin, Robert A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3584-3590

[24] Sunitinib in patients with metastatic renal cell carcinoma [J].

Motzer, Robert J. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Curti, Brendan D. ;

George, Daniel J. ;

Hudes, Gary R. ;

Redman, Bruce G. ;

Margolin, Kim A. ;

Merchan, Jaime R. ;

Wilding, George ;

Ginsberg, Michelle S. ;

Bacik, Jennifer ;

Kim, Sindy T. ;

Baum, Charles M. ;

Michaelson, M. Dror .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524

[25] Kidney Cancer Working Group Report [J].

Naito, Seiji ;

Tomita, Yoshihiko ;

Rha, Sun Young ;

Uemura, Hirotsugu ;

Oya, Mototsugu ;

Song, He Zhi ;

Zhong, Li Han ;

Wahid, Mohamed Ibrahim Bin A. .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 :i51-i56

[26] Clinical biomarkers of response in advanced renal cell carcinoma [J].

Ravaud, A. ;

Schmidinger, M. .

ANNALS OF ONCOLOGY, 2013, 24 (12) :2935-2942

[27] Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis [J].

Rini, Brian I. ;

Garrett, May ;

Poland, Bill ;

Dutcher, Janice P. ;

Rixe, Olivier ;

Wilding, George ;

Stadler, Walter M. ;

Pithavala, Yazdi K. ;

Kim, Sinil ;

Tarazi, Jamal ;

Motzer, Robert J. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (05) :491-504

[28] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial [J].

Rini, Brian I. ;

Escudier, Bernard ;

Tomczak, Piotr ;

Kaprin, Andrey ;

Szczylik, Cezary ;

Hutson, Thomas E. ;

Michaelson, M. Dror ;

Gorbunova, Vera A. ;

Gore, Martin E. ;

Rusakov, Igor G. ;

Negrier, Sylvie ;

Ou, Yen-Chuan ;

Castellano, Daniel ;

Lim, Ho Yeong ;

Uemura, Hirotsugu ;

Tarazi, Jamal ;

Cella, David ;

Chen, Connie ;

Rosbrook, Brad ;

Kim, Sinil ;

Motzer, Robert J. .

LANCET, 2011, 378 (9807) :1931-1939

[29] Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib [J].

Rini, Brian I. ;

Cohen, Darrel P. ;

Lu, Dongrui R. ;

Chen, Isan ;

Hariharan, Subramanian ;

Gore, Martin E. ;

Figlin, Robert A. ;

Baum, Michael S. ;

Motzer, Robert J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (09) :763-773

[30] Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker [J].

Robinson, Emily S. ;

Khankin, Eliyahu V. ;

Karumanchi, S. Ananth ;

Humphreys, Benjamin D. .

SEMINARS IN NEPHROLOGY, 2010, 30 (06) :591-601

← 1 2 3 4 →